Tempest Therapeutics (TPST) news
Recent news
Tempest Therapeutics - appoints Nicholas Rossettos as CFO, principal financial and accounting officer effective Sept 1, 2026 - SEC filing
AInvest Wire · 6d agoTempest Therapeutics - files to offer up to 8,910,579 shares - SEC filing
Tempest Therapeutics, Inc. (Nasdaq: TPST) has announced registered direct offering of up to 1,172,414 shares of its common stock, or common stock equivalents, at an offering price of $3.625 per share. The offering is priced at-the-market under Nasdaq rules and is part of a broader capital-raising…
AInvest Wire · Aug 21, 2026Tempest Therapeutics - Co and Senlang to develop TPST-4003 with trial in China for MG and MS
Tempest Therapeutics Co and Senlang have announced a collaboration to develop TPST-4003, a novel therapeutic candidate, with clinical trials planned in China for the treatment of myasthenia gravis (MG) and multiple sclerosis (MS) [1]. The partnership aims to leverage the strengths of both companies…
AInvest Wire · Jul 21, 2026Tempest Therapeutics - first patient dosing for TPST-4003 trial expected in Q4 2026
AInvest Wire · Jul 21, 2026Tempest Therapeutics - selling stockholders may offer up to 2.43 mln shares of Tempest Therapeutics common stock - SEC filing
Tempest Therapeutics, Inc. (Nasdaq: TPST) has disclosed in a recent SEC filing that selling stockholders may offer up to 2.43 million shares of the company’s common stock, according to a registration statement on Form S-3. The filing indicates that the shares are registered for resale under a shelf…
AInvest Wire · Jun 26, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.